Another study found that 50% of cancer patients (e.g., breast, colorectal, or non–small-cell lung cancer) at high risk for FN received G-CSF as primary prophylaxis, while up to 21% of cancer patients at little or no risk for FN received a G-CSF [5]. The gene discussed is CSF3; the disease is lung cancer.